Royalty Pharma (RPRX) Operating Expenses (2019 - 2026)

Royalty Pharma (RPRX) has 8 years of Operating Expenses data on file, last reported at $67.5 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 98.26% year-over-year to $67.5 million; the trailing twelve-month figure through Mar 2026 stood at $852.1 million (up 134.46% YoY), and the FY2025 full-year result was $818.7 million, down 15.7% from the prior year.
• Operating Expenses eased to $67.5 million in Q1 2026, from $233.6 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $1.0 billion in Q4 2022 to a low of -$170.4 million in Q3 2024.
• A 5-year average of $273.5 million and a median of $233.6 million in 2025 frame the typical range for Operating Expenses.
• Peak annual rise in Operating Expenses reached 1479.41% in 2024, while the deepest fall reached 144.27% in 2024.
• Tracing RPRX's Operating Expenses over 5 years: stood at $1.0 billion in 2022, then plunged by 101.61% to -$16.8 million in 2023, then soared by 1479.41% to $232.1 million in 2024, then advanced by 0.64% to $233.6 million in 2025, then tumbled by 71.09% to $67.5 million in 2026.
• Business Quant data shows RPRX's Operating Expenses at $67.5 million in Q1 2026, $233.6 million in Q4 2025, and $182.1 million in Q3 2025.